The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
With thousands of press releases published each week, it can be difficult to keep up with everything on . To help healthcare ...
Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...
The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...
Biogen announced that the FDA has approved a monthly maintenance dosing version of Leqembi, its intravenously (IV) ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...
Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and FDA approval for Alzheimer's drug Leqembi. Cipla surpasses profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results